Ipsen secures a deal with Simcere Zaiming for a Chinese-developed ADC, SIM0613, potentially worth over $1bn. The drug targets LRRC15, showing promise in preclinical models. Ipsen aims to launch a Phase I trial in 2026. This move aligns with Ipsen’s strategy to become a key player in oncology, adding over 20 programs since 2020.

ADC deals have surged in 2025, with many pharma companies investing in this growing market. Ipsen’s move follows similar deals by Boehringer Ingelheim and Roche, reflecting the industry’s interest in ADC technology. Chinese companies, like Kelun-Biotech, have been active in ADC deals, contributing to the modality’s development.

Simcere Zaiming’s work has attracted attention, with AbbVie also securing a deal with the company this year. Ipsen’s bold vision in oncology is evident through this ADC deal, reinforcing its commitment to innovation. The future of oncology looks promising, with ADCs playing a crucial role in cancer treatment advancements.

Read more at Yahoo Finance: Ipsen outlays $1bn for China-based Simcere’s preclinical ADC